Skip to main content

Table 3 Trials of 2 nd generation TKI in acquired resistance setting

From: Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer

  N OR% mPFS (mo) mOS (mo)
Afatinib     
LUX LUNG I trial 40     
Afatinib 390 7 3.3 10.8
Placebo 195 <1 1.1 12.0
LUX LUNG IV trial 42 61 8.2 4.4 19
XL647     
Phase II trial52 41 3 3.6 16.1
  1. <, less than.